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Abstract 
Background: While patient‑reported treatment dissatisfaction is considered an important factor in determining the 
success of substance use disorder treatment, the levels of dissatisfaction with opioid agonist therapies (OAT) and 
its relationship with the risk of fentanyl exposure have not been characterized in the context of the ongoing opioid 
overdose crisis in the US and Canada. Our primary hypothesis was that OAT dissatisfaction was associated with an 
increased odds of fentanyl exposure.
Methods: Our objective was to examine self‑reported treatment satisfaction among OAT patients in Vancouver, 
Canada and the association with fentanyl exposure. Longitudinal data were derived from 804 participants on OAT 
enrolled in two community‑recruited harmonized prospective cohort studies of people who use drugs in Vancouver 
between 2016 and 2018 via semi‑annual interviews and urine drug screens (UDS). We employed multivariable gener‑
alized estimating equations to examine the relationship between OAT dissatisfaction and fentanyl exposure.
Results: Out of 804 participants (57.0% male), 222 (27.6%) reported being dissatisfied with OAT at baseline and 1070 
out of 1930 observations (55.4%) had fentanyl exposure. The distribution of OAT reported in the sample was metha‑
done (n = 692, 77.7%), buprenorphine‑naloxone (n = 82, 9.2%), injectable OAT (i.e., diacetylmorphine or hydromor‑
phone; (n = 65, 7.3%), slow‑release oral morphine (n = 44, 4.9%) and other/study medication (n = 8, 1.0%). In the mul‑
tivariable analysis, OAT dissatisfaction was positively associated with fentanyl exposure (AOR = 1.34; 95% CI: 1.08–1.66).
Conclusions: A substantial proportion of OAT patients in our sample reported dissatisfaction with their OAT, and 
more than half were exposed to fentanyl. We also found that those who were dissatisfied with their OAT were more 
likely to be exposed to fentanyl. These findings demonstrate the importance of optimizing OAT satisfaction in the 
context of the ongoing opioid overdose crisis.
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Introduction
The United States and Canada are facing an overdose cri-
sis that is being driven in large part by the introduction 
of illicitly-manufactured fentanyl and its analogues into 
the illicit drug supply [1]. In the United States, the rate 
of drug overdose deaths involving synthetic opioids other 
than methadone, such as fentanyl and its analogs, has 
increased 33-fold from 0.3 deaths per 100,000 population 
in 1990 to 9.9 in 2018 [2]. In British Columbia, Canada 
between 2015 and 2017, fentanyl was detected in 79% of 
overdose deaths [3].
Opioid agonist therapy (OAT) with methadone, 
buprenorphine and other long-acting opioids are a vital 
treatment for opioid use disorder and have been shown 
to be superior to withdrawal management in treatment 
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retention and reduction of opioid use, morbidity and 
all-cause mortality [4–8]. In British Columbia, metha-
done and buprenorphine/naloxone are considered first 
line OAT treatments with slow release oral morphine 
as an alternative, and injectable opioid agonist therapy 
(iOAT) with hydromorphone or diacetylmorphine as an 
intensive treatment option [9]. Despite the recent scale 
up of OAT programs, the provincial rate of paramedic 
attended overdoses has increased four-fold from January 
2015 to March 2019, three years after the 2016 declara-
tion of a public health emergency secondary to the opioid 
overdose crisis [1].
Previous studies have suggested that a patient’s per-
ceived treatment satisfaction is a key determinant of the 
success of the OAT. For example, patients who were dis-
satisfied with OAT have been shown to be more likely 
to report increased side effects and continued illicit 
substance use [10–12]. Conversely, satisfaction with 
OAT has been associated with significantly higher treat-
ment retention rates, reduced drug use at one year fol-
low up and perceived improvement in social, physical 
and emotional well-being [13–16]. The existing literature 
evaluating patient satisfaction with OAT suggests that 
satisfaction may be improved by reducing programmatic 
demands, addressing social and medical needs, reduc-
ing stigma experienced by people on OAT, expanding 
access for different OAT options and implementing mod-
els of service delivery that incorporate patient-centered 
approaches [17]. The World Health Organization (WHO) 
also advises to assess treatment satisfaction for patients 
who are receiving treatment for substance use disorder 
[18]. However, in the context of the ongoing opioid over-
dose crisis, we are unaware of any study that has exam-
ined the role of treatment satisfaction and overdose risk 
among OAT patients.
Given the recent increase of fentanyl in the illicit 
drug supply and resulting elevated risk of overdose, it is 
important to understand the levels of satisfaction among 
individuals on OAT and whether treatment satisfaction 
is associated with treatment retention and the risk of 
fentanyl exposure. Therefore, we sought to examine self-
reported treatment dissatisfaction among OAT patients 
in Vancouver, Canada. This study had three hypotheses: 
(1) Dissatisfaction with OAT will be associated with the 
increased odds of discontinuation of OAT; (2) Discon-
tinuation of OAT will be associated with increased odds 
of fentanyl exposure; and (3) Among those retained on 
OAT, OAT dissatisfaction will be associated with the 
increased odds of fentanyl exposure. We also tested all 
hypotheses restricting to patients on methadone spe-
cifically as the majority of the OAT patients in our study 
setting were on methadone at the time of the study in 
2016–2018 [1].
Methods
The Vancouver Injection Drug Users Study (VIDUS) 
and the AIDS Care Cohort to evaluate Exposure to Sur-
vival Services (ACCESS) are active open prospective 
cohort studies of adults who use illicit drugs in Vancou-
ver, Canada. These cohorts have been described in detail 
in past studies [19, 20]. In brief, participants have been 
recruited through referrals, word of mouth and street 
outreach primarily in the Downtown Eastside neigh-
bourhood of Vancouver, which is characterized by high 
rates of illicit drug use [21]. VIDUS enrolls HIV-negative 
persons who report injecting an illicit drug at least once 
and ACCESS enrolls HIV-positive individuals who report 
using an illicit drug (not including cannabis, which was 
illegal during almost all of the study period) in the month 
preceding enrollment. Other eligibility criteria include 
being aged 18 years or older, residing in the greater Van-
couver region and providing written informed consent 
in both cohorts. The study instruments and follow-up 
procedures for each study are harmonized to permit 
combined analyses. At baseline and semi-annually there-
after, participants complete an interviewer-administered 
questionnaire obtaining socio-demographic data as 
well as information pertaining to drug use patterns, risk 
behaviours, and health care utilization. They also are 
administered a multi-panel qualitative urine drug screen 
(UDS), BTNX Rapid Response™ Multi-Drug Test Panel 
(Markham, ON, Canada) at each study visit. Participants 
receive a $40 (CDN) honorarium for each study visit. The 
University of British Columbia/Providence Health Care 
Research Ethics Board provided ethical approval for both 
studies.
The question about OAT satisfaction was added to 
the questionnaire in December 2016. Therefore, for the 
present study, we used data collected between Decem-
ber 2016 and November 2018. The observations were 
restricted to those with reports of being enrolled in 
any OAT at some point in the past six months for test-
ing Hypotheses 1 and 2. For Hypothesis 3, we further 
restricted the observations to those with reports of being 
currently enrolled in any OAT. A sub analysis was per-
formed for all three hypotheses by restricting OAT type 
to methadone.
The primary outcome for the Hypothesis 1 was dis-
continuation of OAT in the past six months (yes vs. 
no), defined as being enrolled in OAT at some point 
during the past six months, but not being enrolled 
in any OAT at the time of the interview. The primary 
outcome in Hypothesis 2 and 3 was fentanyl expo-
sure, defined as a positive UDS result for fentanyl at 
the time of the interview. Fentanyl positive UDS was 
selected as an objective marker of overdose risk. Fen-
tanyl has contaminated the illicit drug supply to a great 
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extent in our study setting and has been the principal 
driver of the opioid overdose crisis [1]. Illicit fentanyl is 
also detected in non-opioid drugs [1, 3]; therefore, we 
decided to use fentanyl positive UDS as a more objec-
tive marker of overdose risk. The cut-off value of the 
calibrator for fentanyl positive screens is 100 ng/mL of 
fentanyl or 20 ng/mL of norfentanyl, and is believed to 
detect exposure to fentanyl within a maximum of past 
three days [22].
The primary explanatory variable of interest in Hypoth-
eses 1 and 3 was dissatisfaction with OAT as measured 
during the interview by asking “Overall, how satisfied 
were you with the medication treatment you received?”. 
A five-point scale was used including the following selec-
tions “very unsatisfied,” “unsatisfied,” “neutral,” “satisfied” 
and “very satisfied”. We dichotomized the variable as: 
“very unsatisfied” or “unsatisfied” vs. “neutral”, “satisfied” 
or “very satisfied”. The primary explanatory variable for 
hypothesis 2 was discontinuation of OAT in the past six 
months (yes vs. no).”
For all hypotheses, we also considered secondary 
explanatory variables that might confound the primary 
exposure-outcome relationships based on our clinical 
experience and previous research [23]. These included 
socio-demographic characteristics, including: age (per 
year older); self-identified gender (male vs. non-male); 
ancestry (white vs. non-white); and homelessness in the 
past 6 months. Drug-use variables referred to behav-
iours in the previous 6 months, and included: stimulant 
use (i.e., cocaine, crack or crystal methamphetamine 
use; ≥ daily vs. < daily) and injection drug use. We also 
included the most recent OAT medication type (metha-
done vs. other). Further, any illicit opioid use (≥ daily 
vs. < daily) was included in the descriptive analyses, but 
not in the multivariable analysis because we hypoth-
esized that it would mediate the relationship between 
OAT dissatisfaction and fentanyl exposure given the high 
levels of contamination of illicit opioids with fentanyl in 
our setting.
First, we compared the baseline sample characteristics 
between those with and without fentanyl exposure, using 
the Pearson’s Chi-squared test (for binary variables) and 
Wilcoxon Rank Sum test (for continuous variables).
In order to test all hypotheses, we used generalized 
estimating equations (GEE) with logit link, which pro-
vided standard errors adjusted by multiple observations 
per person using an exchangeable correlation structure. 
For all three hypotheses, we fit a multivariable GEE 
model by including the primary explanatory variable 
and all secondary explanatory variables that were asso-
ciated with the respective outcomes for each hypothesis 
in unadjusted analyses at p < 0.10. All p-values were two-
sided and tests were considered statistically significant 
at p < 0.05. All statistical analyses were performed using 
SAS version 9.4 (SAS Institute, Cary, NC).
Results
In total, 804 participants were eligible for the present 
analyses. The median age at baseline of this sample was 
47.5  years (interquartile range [IQR] = 37.9–54.6), 458 
(57.0%) were male and 362 (45.0%) self-reported white 
ancestry. Overall, the 804 individuals contributed 1930 
observations and the median number of follow-up visits 
was 2 (IQR: 1–4) per person. The baseline characteristics 
of all participants stratified by fentanyl exposure are pre-
sented in Table  1. Across the 804 particiapnts included 
in the study at baseline, 131 (16.3%) felt very satisfied, 
311 (38.7%) felt satisfied, 140 (17.4%) were neutral, 120 
(14.9%) felt unsatisfied and 102 (12.7%) felt very unsatis-
fied with OAT. In terms of the types of the OAT medi-
cations that participants were on at baseline, methadone 
was the most commonly reported medication (n = 692, 
77.7%), followed by buprenorphine-naloxone (n = 82, 
9.2%), iOAT (i.e., diacetylmorphine or hydromorphone; 
(n = 65, 7.3%), slow-release oral morphine (n = 44, 
4.9%), other/study medication (n = 8, 1.0%). Distribu-
tions of OAT satisfaction scores across the four different 
OAT medication types are depicted in Fig. 1. The break-
down for dissatisfaction among the range of OAT types 
included in the sample at baseline was: methadone 30.8% 
(n = 627), buprenorphine 19.1% (n = 68), oral morphine 
20.9% (n = 43), and iOAT 11.9% (n = 59).
Of the 1930 observations, 180 (9.3%) reported discon-
tinuation of OAT in the past six months. Among 599 
participants who injected drugs in the past six months 
at baseline, 79 (13.2%) injected illicit opioids only, 129 
Table 1 Baseline sample characteristics stratified by fentanyl 
exposure among OAT patients (n = 804)
IQR interquartile range, OAT opioid agonist therapy, UDS urine drug screen
a Denotes activities in the previous six months
b Refers to any route of consumption (i.e., sniffing, snorting, smoking or 
injecting)







Dissatisfaction 140 (33.3) 82 (21.4) 0.0001
Age (median, IQR) 42.8 (35.1–50.9) 51.5 (44.8–56.6)  < .0001
Male gender 229 (54.5) 229 (59.6) 0.117
White 195 (46.4) 167 (43.5) 0.461
Homelessnessa 119 (28.3) 45 (11.7)  < .0001
 ≥ Daily opioid  usea, b 241 (57.4) 36 (9.4)  < .0001
 ≥ Daily stimulant  usea, b 128 (30.5) 98 (25.5) 0.119
Injection drug  usea 378 (90) 221 (57.6)  < .0001
Page 4 of 7Mackay et al. Addict Sci Clin Pract           (2021) 16:26 
(21.5%) injected drugs other than illicit opioids (e.g., 
stimulants), and 391 (65.3%) injected both illicit opioids 
and other drugs. In total, 1070 (55.4%) observations 
had a positive UDS result for fentanyl at the time of the 
interview.
In the multivariable GEE analysis to test Hypoth-
esis 1, OAT dissatisfaction was significantly associ-
ated with discontinuation of OAT (adjusted odds ratio 
[AOR] = 3.72; 95% confidence interval [CI]: 2.66–5.21) 
after adjusting for age, homelessness, daily stimulant 
use and injection drug use. This association was con-
sistent when OAT was restricted to methadone only 
(AOR = 3.59; 95% CI: 2.49–5.18). In the multivariable 
GEE analysis to test Hypothesis 2, OAT discontinua-
tion was significantly associated with fentanyl exposure 
(AOR = 2.05; 95% CI: 1.47–2.84) after adjusting for age, 
homelessness, daily stimulant use and injection drug 
use. Again, this association was consistent when OAT 
was restricted to methadone only (AOR = 2.20; 95% CI: 
1.50–3.21).
The results of the bivariable and multivariable GEE 
analyses for Hypothesis 3 are presented in Table  2. As 
shown, in the final multivariable model after adjusting 
for age, homelessness and injection drug use, dissatisfac-
tion with OAT remained independently and positively 
associated with fentanyl exposure (AOR = 1.34; 95% CI: 
1.08–1.66). This association was consistent when OAT 
type was restricted to methadone (AOR = 1.47; 95% CI: 
1.16–1.87).
Discussion
In our sample of participants on OAT, 27.6% reported 
OAT dissatisfaction at baseline and 9.3% of observa-
tions included reports of OAT discontinuation in the 
past six months. The prevalence of fentanyl exposure in 
all observations was also substantial at 55%. We found 





















































































































Fig. 1 Distributions of OAT satisfaction scores across the four different OAT in the sample at baseline. OAT opioid agonist therapy, iOAT injectable 
opioid agonist therapy with hydromorphone or diacetylmorphine
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that individuals who were dissatisfied with their OAT 
were more likely to have discontinued the OAT, and OAT 
discontinuation was positively associated with fentanyl 
exposure. The relationship between OAT dissatisfaction 
and fentanyl exposure persisted even when the analysis 
was restricted to those who were retained on OAT, and 
after adjusting for potential confounders. These findings 
also remained consistent when we restricted the analyses 
to participants on methadone only.
To our knowledge, this is the first study that demon-
strated the relationship between patient-reported OAT 
dissatisfaction and fentanyl exposure. Our findings indi-
cate that ensuring treatment satisfaction among OAT 
patients could potentially prevent exposure to fentanyl 
and reduce the subsequent risk of overdose. The baseline 
prevalence of OAT dissatisfaction in our study (27.6%) 
was higher than what has been reported in past literature, 
with estimates ranging from 8.1 to 20.6% [11, 24, 25]. 
This could be due to the high rates of potent opioids such 
as fentanyl and its analogues in the illicit drug supply in 
our study setting, making it more challenging to stabi-
lize patients on OAT [3, 9]. Another potential significant 
contributor to dissatisfaction is the regulatory change in 
British Columbia introduced in 2014 to the Methadone 
Maintenance Program, which involved changing the 
methadone formulation [26]. Previous studies reported 
significant increases in the prevalence of heroin injection 
and opioid withdrawal symptoms following this regula-
tory change in our setting [27, 28].
Past literature has shown a range of factors that could 
be associated with OAT dissatisfaction, including fre-
quent use of heroin or cocaine, not feeling respected by 
OAT clinic staff, inadequate methadone doses, increased 
side effects and unmet service needs (such as employ-
ment, housing and finances) [11, 12, 16, 23, 25, 29]. Care 
providers should explore OAT satisfaction with their 
patients and practice patient-centered decision making in 
order to improve satisfaction. As the literature suggests, 
satisfaction with OAT may be improved by reducing pro-
grammatic demands (e.g. allowing for telephone visits, 
longer prescriptions and carry doses where appropriate) 
as well as addressing people’s social and medical needs 
to ensure overall wellbeing [17]. Additionally, access 
should be improved for different OAT options (i.e. sus-
tained release oral morphine, iOAT) and different mod-
els of service delivery that incorporate patient-centered 
approaches.
An important focus for future study should be look-
ing at the unique clinical considerations that apply in the 
case of fentanyl exposed compared to non-exposed indi-
viduals with opioid use disorder. Learning more about 
fentanyl exposure is crucial given that OAT is key for 
overdose prevention and fentanyl is a main driver of the 
overdose crisis in the US and Canada [1, 2]. Further to 
this, the factors which improve retention on OAT should 
be evaluated as a part of the strategy to address the over-
dose crisis.
There are several limitations in this study. Given this 
study was observational, we cannot infer causation 
between OAT dissatisfaction and exposure to fentanyl. 
Further to this, our analysis cannot establish the tempo-
rality between the exposure and outcome, and therefore 
there is a potential that the observed association may 
mean that fentanyl exposure resulted in low satisfac-
tion. As with any observational research, unmeasured 
confounders could exist; however, we tried to reduce 
this bias through adjustment of regression models using 
potential predictors of having a UDS positive for fenta-
nyl. Additionally, as the VIDUS and ACCESS cohorts 
are not random samples, generalizability of the findings 
Table 2 Bivariable and multivariable GEE analyses to estimate the relationship between OAT dissatisfaction and fentanyl exposure
AOR adjusted odds ratio, CI confidence interval, OR odds ratio, OAT opioid agonist therapy
a Denotes behaviours/events in the past 6 months
b Refers to any route of consumption (i.e., sniffing, snorting, smoking or injecting)
Variable Any OAT Restricted to Methadone
OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI)
OAT dissatisfaction 1.20 (1.00–1.44) 1.34 (1.08–1.66) 1.30 (1.07–1.58) 1.47 (1.16–1.87)
Age (per year increase) 0.94 (0.93–0.96) 0.95 (0.94–0.97) 0.94 (0.92–0.95) 0.95 (0.93–0.96)
Male gender 0.89 (0.68–1.15) 0.86 (0.64–1.15)
White 1.12 (0.86–1.45) 1.04 (0.78–1.40)
Homelessnessa 1.87 (1.38–2.53) 1.31 (0.93–1.84) 1.94 (1.37–2.75) 1.44 (0.97–2.13)
 ≥ Daily stimulant  usea,b 1.20 (0.96–1.50) 1.20 (0.93–1.56)
Injection drug  usea 4.49 (3.47–5.82) 4.23 (3.25–5.52) 4.49 (3.37–5.99) 4.24 (3.15–5.71)
Most recent OAT = methadone 0.92 (0.71–1.20) NA NA
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could be limited. Part of the data used in the study was 
self-reported and therefore could be subject to reporting 
biases, however self-reported behavioural data has been 
shown to be generally accurate among adult drug-using 
populations [30]. Also, due to the small sample size, we 
were unable to stratify the analyses by all four OAT medi-
cation types. There could potentially be differences in the 
results by OAT medication types. Lastly, the lack of mul-
tidimensionality in the OAT satisfaction scoring, due to 
limitations in survey length, makes it impossible to dis-
cern what it is that is causing individuals to be dissatis-
fied. Future research should explore this topic through a 
qualitative study design.
Conclusion
Among our sample of participants on OAT in Vancouver, 
Canada, 27.6% were dissatisfied with their OAT, 9.3% dis-
continued their OAT in the last six months and over half 
had a UDS positive for fentanyl. We found that OAT dis-
satisfaction remained independently associated with fen-
tanyl exposure after adjusting for potential confounders. 
Given the current opioid overdose crisis in the United 
States and Canada and the risk of overdose and death 
with ongoing illicit opioid use, these findings demon-
strate the importance of optimizing patient satisfaction 
with their OAT in order to potentially reduce exposure to 
fentanyl [2, 31].
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